Abáné J L, Oleaga A, Ramajo V, Casanueva P, Arellano J L, Hillyer G V, Muro A
Lab. Parasitología, Facultad de Farmacia, Universidad de Salamanca, Avda Campo Charro s/n, 37007, Salamanca, Spain.
Vet Parasitol. 2000 Jul 24;91(1-2):33-42. doi: 10.1016/s0304-4017(00)00263-6.
Two strains of mice (NMRI and C57/BL) were each immunized with a 15kDa recombinant Fasciola hepatica fatty acid binding protein (FABP) (Fh15) and challenged percutaneously with Schistosoma bovis cercariae. C57/BL mice immunized with Fh15 had significant reductions in S. bovis worm burden recoveries (72% reductions over controls). When using NMRI mice, Fh15 in Freund's adjuvant failed to induce significant protection against S. bovis. In C57/BL mice, only antibodies to the IgG2a isotype increased after the second immunization and remained high through 8 weeks of S. bovis infection. This is the first time that a heterologous recombinant molecule from F. hepatica has been used in vaccination against S. bovis, obtaining a significant reduction in the number of worms in C57/BL mice.
将两株小鼠(NMRI和C57/BL)分别用15kDa重组肝片吸虫脂肪酸结合蛋白(FABP)(Fh15)免疫,然后经皮用牛血吸虫尾蚴攻击。用Fh15免疫的C57/BL小鼠的牛血吸虫虫体负荷回收率显著降低(比对照组降低72%)。当使用NMRI小鼠时,弗氏佐剂中的Fh15未能诱导出对牛血吸虫的显著保护作用。在C57/BL小鼠中,仅在第二次免疫后IgG2a同种型抗体增加,并在牛血吸虫感染的8周内一直保持高水平。这是首次将来自肝片吸虫的异源重组分子用于牛血吸虫疫苗接种,并使C57/BL小鼠体内的虫体数量显著减少。